Spelling suggestions: "subject:"pgc1 alpha"" "subject:"pgcy1 alpha""
1 |
Resveratrol as a Novel Therapeutic Agent for Treating Duchenne Muscular DystrophyBurt, Matthew 28 October 2013 (has links)
Duchenne Muscular Dystrophy (DMD) is an x-linked neuromuscular disease that is caused by an absence of dystrophin protein, rendering skeletal muscle more susceptible to contraction-induced damage. One therapeutic strategy focuses on increasing the expression of endogenous utrophin A, a dystrophin homologue. Interestingly, slow muscle is more resistant to the dystrophic pathology and has increased utrophin A expression (Webster 1998; Gramolini 2001b). These observations led researchers to explore the therapeutic potential of stimulating the slow, oxidative myogenic program (SOMP) in the mdx context. Beneficial adaptations were seen with pharmacological activation of PPARδ and AMPK. We treated mdx mice with resveratrol (~100mg/kg/day), a putative SIRT1 activator, for 6-7 weeks and evaluated the activity of phenotypic modifiers that are known to influence the SOMP. SIRT1 activity and protein levels increased significantly, as well as downstream PGC-1α activity. There was evidence of a fibre type conversion as the treated mice had a higher proportion of the slow myosin heavy chain isoforms in both the EDL and Soleus skeletal muscles. Utrophin A protein levels showed modest, but consistent increases with resveratrol treatment. Finally, histological analysis revealed improvements in central nucleation and fibre size variability. These findings were promising, but raised the question of whether modifying the treatment regimen may result in greater therapeutic benefits. Surprisingly, we discovered that an elevated dose of 500mg/kg/day was ineffective in its promotion of the SOMP. SIRT1 was not activated and there was no change in utrophin A levels with resveratrol treatment. Taken together, this study demonstrates that resveratrol has the ability to promote the SOMP through SIRT1 and PGC-1α activation. It also highlights the importance of selecting an appropriate dose of resveratrol to maximize its effectiveness.
|
2 |
Resveratrol as a Novel Therapeutic Agent for Treating Duchenne Muscular DystrophyBurt, Matthew January 2013 (has links)
Duchenne Muscular Dystrophy (DMD) is an x-linked neuromuscular disease that is caused by an absence of dystrophin protein, rendering skeletal muscle more susceptible to contraction-induced damage. One therapeutic strategy focuses on increasing the expression of endogenous utrophin A, a dystrophin homologue. Interestingly, slow muscle is more resistant to the dystrophic pathology and has increased utrophin A expression (Webster 1998; Gramolini 2001b). These observations led researchers to explore the therapeutic potential of stimulating the slow, oxidative myogenic program (SOMP) in the mdx context. Beneficial adaptations were seen with pharmacological activation of PPARδ and AMPK. We treated mdx mice with resveratrol (~100mg/kg/day), a putative SIRT1 activator, for 6-7 weeks and evaluated the activity of phenotypic modifiers that are known to influence the SOMP. SIRT1 activity and protein levels increased significantly, as well as downstream PGC-1α activity. There was evidence of a fibre type conversion as the treated mice had a higher proportion of the slow myosin heavy chain isoforms in both the EDL and Soleus skeletal muscles. Utrophin A protein levels showed modest, but consistent increases with resveratrol treatment. Finally, histological analysis revealed improvements in central nucleation and fibre size variability. These findings were promising, but raised the question of whether modifying the treatment regimen may result in greater therapeutic benefits. Surprisingly, we discovered that an elevated dose of 500mg/kg/day was ineffective in its promotion of the SOMP. SIRT1 was not activated and there was no change in utrophin A levels with resveratrol treatment. Taken together, this study demonstrates that resveratrol has the ability to promote the SOMP through SIRT1 and PGC-1α activation. It also highlights the importance of selecting an appropriate dose of resveratrol to maximize its effectiveness.
|
3 |
Estudo da variação da expressão de PGC-1 alfa na reprogramação e diferenciação de células-tronco pluripotentes induzidas / A study of the variation in expression of PGC-1alfa on the reprogramming and differentiation of induced pluripotent stem cellsRosas, Graça Correia 15 July 2016 (has links)
As doenças cardiovasculares representam a maior causa de mortalidade a nível mundial. Desde o conhecimento da importância da mitocôndria no metabolismo do cardiomiócito, alterações no funcionamento desta organela têm sido associadas a um dos principais causadores do infarto do miocárdio e consequente morte celular. O cofator de transcrição PGC-1alfa tem sido alvo de diversos estudos relacionados com o metabolismo celular devido à sua forte participação na biogênese mitocondrial. Considerando a limitação de material biológico para o estudo de doenças cardíacas, muito se tem investido no estudo de células-tronco pluripotentes induzidas (iPSCs). Esta tese teve como principal objetivo a avaliação dos efeitos da variação da expressão de PGC-1alfa em iPSCs e na sua diferenciação em cardiomiócitos. Após estabelecimento de um protocolo de reprogramação celular, em que ocorre geração de iPSCs a partir de fibroblastos humanos, induzimos a inibição da expressão de PGC-1alfa em 50% e 70% pelo uso de vetores lentivirais, e analisamos o estado de pluripotência através da avaliação de expressão genica e proteica dos principais marcadores - SSEA4, TRA-1-60, OCT4, NANOG, SOX2, REX1, TRA-1-81. Não observamos diferenças significativas no conteúdo destes marcadores entre os clones de iPSC controle e inibidos. Estabelecemos um protocolo de diferenciação de iPSCs em cardiomiócitos com elevada taxa de reprodutibilidade, através da adaptação de protocolos descritos na literatura, e submetemos estas iPSCs à diferenciação. As células geradas pela diferenciação do clone controle apresentaram características típicas de cardiomiócito: contratilidade e alta expressão molecular de troponina T e troponina I. Em contraste, as células com 70% de inibição de PGC-1alfa se mostraram incapazes de contrair e com baixa expressão de troponina. Através de uma análise dos níveis de expressão genica e proteica de diversos marcadores expressos durante o processo de diferenciação (T, NKX2.5, MIXL1, MYL7, ISL1), observamos que o clone com maior inibição de PGC-1alfa apresentou sempre níveis de expressão diminuídos em relação aos clones controle. Em conclusão, podemos afirmar que o PGC-1alfa não interfere com as características de auto-renovação e pluripotência das iPSCs mas possui um papel essencial na diferenciação de células-tronco pluriotentes induzidas em cardiomiócitos. Os resultados obtidos contribuem para informações preliminares acerca do desenvolvimento de iPSCs com inibição da expressão de PGC-1alfa durante a diferenciação cardíaca, mas estudos relativos ao potencial papel deste cofator durante o desenvolvimento cardíaco in vivo ainda precisam ser aprofundados, utilizando outros modelos de estudo / Cardiovascular diseases are the leading cause of mortality worldwide. Since the knowledge of the importance of mitochondria in the cardiomyocyte metabolism, changes in the functioning of this organelle has been associated with one of the main causes of myocardial infarction and subsequent cell death. The transcriptional cofactor PGC-1alpha has been subjected to several studies related to cell metabolism due to its strong involvement in mitochondrial biogenesis. Considering the limitations of biological material in the study of heart disease, there has been a lot of investment in the study of induced pluripotent stem cells (iPSCs). The main objective of this thesis was to evaluate the effects of the variation in expression of PGC-1alpha in iPSCs and it\'s differentiation in cardiomyocytes. After the estabilshment of a cellular reprogramming protocol, where iPSCs is generated from human fibroblasts, the expression of PGC-1alpha was induced by 50% and 70% with the use of lentiviral vectors and the state of pluripotency was determined by analyzing the gene and protein expression of the main markers - SSEA4, TRA- 1-60, OCT4, NANOG, SOX2, REX1, TRA- 1- 81. There were no significant differences observed in the content of these markers between the iPSC clones control and inhibited. A protocol for the differentiation of iPSCs into cardyomyocites was established with a high reproducibility rate, by adapting existing protocols in the general literature, submiting these iPSCs into diferentiation. The cells generated from the differentiation of the control clone showed typical characteristis of cardiomyocytes: contractility and high molecular expression of troponin T and troponin I. In contrast, the cells with 70% inhibition PGC-1alpha were unable to contract and had low troponin expression. Through an analysis of gene expression and protein levels of several markers expressed during the differentiation process (T, Nkx2.5, MIXL1, MYL7, ISL1), the clone with greater inhibition of PGC-1alpha always showed decreased expression levels compared to control clones. In conclusion, we can say that the PGC-1alpha does not interfere with the characteristics of self-renewal and pluripotency of iPSCs but has an essential role in the differentiation of pluripotent stem cells induced into cardiomyocytes. These results were obtained thanks an original approche based on iPSC technology enabling genetic modifications of the cells and controled differentiation into cardiomyocytes, but the potential role of PGC-1alpha on in vivo cardiac development or cardiomyocytes maturation remaisn to be evaluated using other models
|
4 |
Estudo da variação da expressão de PGC-1 alfa na reprogramação e diferenciação de células-tronco pluripotentes induzidas / A study of the variation in expression of PGC-1alfa on the reprogramming and differentiation of induced pluripotent stem cellsGraça Correia Rosas 15 July 2016 (has links)
As doenças cardiovasculares representam a maior causa de mortalidade a nível mundial. Desde o conhecimento da importância da mitocôndria no metabolismo do cardiomiócito, alterações no funcionamento desta organela têm sido associadas a um dos principais causadores do infarto do miocárdio e consequente morte celular. O cofator de transcrição PGC-1alfa tem sido alvo de diversos estudos relacionados com o metabolismo celular devido à sua forte participação na biogênese mitocondrial. Considerando a limitação de material biológico para o estudo de doenças cardíacas, muito se tem investido no estudo de células-tronco pluripotentes induzidas (iPSCs). Esta tese teve como principal objetivo a avaliação dos efeitos da variação da expressão de PGC-1alfa em iPSCs e na sua diferenciação em cardiomiócitos. Após estabelecimento de um protocolo de reprogramação celular, em que ocorre geração de iPSCs a partir de fibroblastos humanos, induzimos a inibição da expressão de PGC-1alfa em 50% e 70% pelo uso de vetores lentivirais, e analisamos o estado de pluripotência através da avaliação de expressão genica e proteica dos principais marcadores - SSEA4, TRA-1-60, OCT4, NANOG, SOX2, REX1, TRA-1-81. Não observamos diferenças significativas no conteúdo destes marcadores entre os clones de iPSC controle e inibidos. Estabelecemos um protocolo de diferenciação de iPSCs em cardiomiócitos com elevada taxa de reprodutibilidade, através da adaptação de protocolos descritos na literatura, e submetemos estas iPSCs à diferenciação. As células geradas pela diferenciação do clone controle apresentaram características típicas de cardiomiócito: contratilidade e alta expressão molecular de troponina T e troponina I. Em contraste, as células com 70% de inibição de PGC-1alfa se mostraram incapazes de contrair e com baixa expressão de troponina. Através de uma análise dos níveis de expressão genica e proteica de diversos marcadores expressos durante o processo de diferenciação (T, NKX2.5, MIXL1, MYL7, ISL1), observamos que o clone com maior inibição de PGC-1alfa apresentou sempre níveis de expressão diminuídos em relação aos clones controle. Em conclusão, podemos afirmar que o PGC-1alfa não interfere com as características de auto-renovação e pluripotência das iPSCs mas possui um papel essencial na diferenciação de células-tronco pluriotentes induzidas em cardiomiócitos. Os resultados obtidos contribuem para informações preliminares acerca do desenvolvimento de iPSCs com inibição da expressão de PGC-1alfa durante a diferenciação cardíaca, mas estudos relativos ao potencial papel deste cofator durante o desenvolvimento cardíaco in vivo ainda precisam ser aprofundados, utilizando outros modelos de estudo / Cardiovascular diseases are the leading cause of mortality worldwide. Since the knowledge of the importance of mitochondria in the cardiomyocyte metabolism, changes in the functioning of this organelle has been associated with one of the main causes of myocardial infarction and subsequent cell death. The transcriptional cofactor PGC-1alpha has been subjected to several studies related to cell metabolism due to its strong involvement in mitochondrial biogenesis. Considering the limitations of biological material in the study of heart disease, there has been a lot of investment in the study of induced pluripotent stem cells (iPSCs). The main objective of this thesis was to evaluate the effects of the variation in expression of PGC-1alpha in iPSCs and it\'s differentiation in cardiomyocytes. After the estabilshment of a cellular reprogramming protocol, where iPSCs is generated from human fibroblasts, the expression of PGC-1alpha was induced by 50% and 70% with the use of lentiviral vectors and the state of pluripotency was determined by analyzing the gene and protein expression of the main markers - SSEA4, TRA- 1-60, OCT4, NANOG, SOX2, REX1, TRA- 1- 81. There were no significant differences observed in the content of these markers between the iPSC clones control and inhibited. A protocol for the differentiation of iPSCs into cardyomyocites was established with a high reproducibility rate, by adapting existing protocols in the general literature, submiting these iPSCs into diferentiation. The cells generated from the differentiation of the control clone showed typical characteristis of cardiomyocytes: contractility and high molecular expression of troponin T and troponin I. In contrast, the cells with 70% inhibition PGC-1alpha were unable to contract and had low troponin expression. Through an analysis of gene expression and protein levels of several markers expressed during the differentiation process (T, Nkx2.5, MIXL1, MYL7, ISL1), the clone with greater inhibition of PGC-1alpha always showed decreased expression levels compared to control clones. In conclusion, we can say that the PGC-1alpha does not interfere with the characteristics of self-renewal and pluripotency of iPSCs but has an essential role in the differentiation of pluripotent stem cells induced into cardiomyocytes. These results were obtained thanks an original approche based on iPSC technology enabling genetic modifications of the cells and controled differentiation into cardiomyocytes, but the potential role of PGC-1alpha on in vivo cardiac development or cardiomyocytes maturation remaisn to be evaluated using other models
|
Page generated in 0.0274 seconds